Abstract Body

Inflammation associated with increased risk of comorbidities persists in people living with HIV (PLWH) on combination antiretroviral therapy (ART). Low-dose methotrexate (MTX) is an anti-inflammatory treatment for rheumatological disorders. A recent placebo-controlled trial (ACTG A5314) of low-dose MTX in PLWH found no changes in plasma inflammatory indices, but numbers of total and cycling (Ki-67+) CD4 and CD8 T cells decreased in the low-dose MTX arm.

Effects of MTX (up to 100nM) on the release of IL-1ß, IL-6, IFNγ TNF, and IL-2 by PBMCs from PLWH (n=6) or HIV-uninfected controls (n=6) was measured by ELISA in culture supernatant following exposure to LPS, flagellin, antibodies to CD3 and CD28 (anti-CD3/CD28), or medium control. Effects of MTX on T cell proliferation (CellTrace Violet dilution), activation (CD69 and CD25 expression), and numbers from PLWH (n=6) or HIV-uninfected controls (n=11) were measured by flow cytometry following stimulation with anti-CD3/CD28, IL-2, IL-7, IL-15, or medium control.

At concentrations up to 100nM, MTX treatment did not inhibit IL-1ß and IL-6 release in response to LPS or flagellin; IFNγ, TNF, and IL-2 release in response to anti-CD3/CD28; or T cell activation (CD69 and CD25 expression) in response to stimulation with anti-CD3/CD28, IL-2, IL-7, or IL-15. T cell proliferative responses to anti-CD3/CD28 were inhibited by MTX (median IC50 = 42.07nM), but IC50s were similar among cells from PLWH and controls (P = 0.099), with similar results seen for IL-2, IL-7, and IL-15. MTX treatment during anti-CD3/CD28 stimulation also resulted in a significant decrease in T cell numbers, suggesting activation-induced cell death. Addition of folinic acid (1μM) restored T cell proliferation to anti-CD3/CD28 stimulation, but did not rescue cell numbers.

Our findings indicate that MTX at concentrations up to 100 nM does not inhibit expression of IFNγ, TNF, and IL-2 in response to T cell receptor (TCR) stimulation or IL-1ß and IL-6 after stimulation with the TLR4 and TLR5 agonists LPS and flagellin in vitro. Proliferation of CD4 and CD8 T cells in response to TCR and common gamma chain cytokine stimulation is profoundly reduced by MTX and is associated with cell death in vitro. Folinic acid could restore T cell proliferation, but did not fully rescue cell death. Our data are fully consistent with the in vivo effects of MTX in PLWH suggesting that the major effect of MTX on immune function is an inhibition of cellular proliferation.